Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain – Pipeline Review, H2 2016, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 6, 27, 29, 1, 119, 21 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 1 molecules, respectively.

Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

2-BBB Medicines BV
AbbVie Inc
Acadia Pharmaceuticals Inc
Achelios Therapeutics Inc
Adynxx Inc
Aevi Genomic Medicine Inc
Affectis Pharmaceuticals AG
Amura Holdings Ltd
AnaBios Corp
Anavex Life Sciences Corp
AngioChem Inc
APT Therapeutics Inc
Aquilus Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Asahi Kasei Pharma Corp
Astellas Pharma Inc
AstraZeneca Plc
BCI Pharma
Biogen Inc
BioLineRx Ltd
Biomar Microbial Technologies
Bionomics Ltd
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd
Cara Therapeutics Inc
Catalyst Biosciences Inc
Cavion LLC
Centrexion Therapeutics Corp
Cerecor Inc
Chromocell Corp
Circuit Therapeutics Inc
CLL Pharma SA
Colby Pharmaceutical Company
ContraVir Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
Cytogel Pharma LLC
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Company Ltd
Develco Pharma Schweiz AG
Dompe Farmaceutici SpA
Eisai Co Ltd
Eli Lilly and Company
Endece LLC
Evec Inc
Genecode AS
Glenmark Pharmaceuticals Ltd
Glialogix Inc
Grunenthal GmbH
GW Pharmaceuticals Plc
Hydra Biosciences Inc
Immune Pharmaceuticals Inc
Inpellis Inc
Integral Molecular Inc
Intellipharmaceutics International Inc
iX Biopharma Ltd
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Nhwa Pharmaceutical Corp Ltd
Johnson & Johnson
Kareus Therapeutics SA
Knopp Biosciences LLC
Kolon Life Science Inc
KPI Therapeutics Inc
Laboratorios Del Dr Esteve SA
Lexicon Pharmaceuticals Inc
Lohocla Research Corp
Lpath Inc
Mapi Pharma Ltd
Medestea Research & Production SpA
Medifron DBT Co Ltd
Medisyn Technologies Inc
Medy-Tox Inc
Merck & Co Inc
Nanomerics Ltd
Neurim Pharmaceuticals Ltd
Neurocentrx Pharma Ltd
NeuroCycle Therapeutics GmbH
NeuroMax
NeurOp Inc
Newron Pharmaceuticals SpA
Nippon Chemiphar Co Ltd
NoNO Inc
Novaremed Ltd
Novartis AG
NsGene A/S
Omeros Corp
Orion Oyj
Patagonia Pharmaceuticals LLC
PeriphaGen Inc
Pfizer Inc
Pharmaleads SA
PharmEste Srl
Phosphagenics Ltd
Prismic Pharmaceuticals Inc
RaQualia Pharma Inc
Re-Pharm Ltd
Relmada Therapeutics Inc
Revance Therapeutics Inc
Saniona AB
Scilex Pharmaceuticals Inc
Shionogi & Co Ltd
SK Biopharmaceuticals Co Ltd
Sphaera Pharma Pvt Ltd
Spherium Biomed SL
Sunovion Pharmaceuticals Inc
Syntrix Biosystems Inc
Takeda Pharmaceutical Company Ltd
Teva Pharmaceutical Industries Ltd
Theranexus SAS
Theravasc Inc
Toray Industries Inc
Torrent Pharmaceuticals Ltd
Trevena Inc
Trigemina Inc
Virobay Inc
VistaGen Therapeutics Inc
Vitality Biopharma Inc
Yuhan Corp
Yungjin Pharm Co Ltd
Zynerba Pharmaceuticals Inc